DURHAM, N.C., Feb. 4, 2012 /PRNewswire/ --Argos Therapeutics Inc. today announced that updated results from an open label Phase 2 study of its Arcelis' immunotherapy, AGS-003, in combination with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results